Hubei Biocause Heilen Pharmaceutical Balance Sheet Health
Financial Health criteria checks 6/6
Hubei Biocause Heilen Pharmaceutical has a total shareholder equity of CN¥2.3B and total debt of CN¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CN¥2.4B and CN¥141.6M respectively. Hubei Biocause Heilen Pharmaceutical's EBIT is CN¥37.4M making its interest coverage ratio -0.7. It has cash and short-term investments of CN¥1.6B.
Key information
0%
Debt to equity ratio
CN¥0
Debt
| Interest coverage ratio | -0.7x |
| Cash | CN¥1.62b |
| Equity | CN¥2.30b |
| Total liabilities | CN¥141.64m |
| Total assets | CN¥2.44b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 301211's short term assets (CN¥1.9B) exceed its short term liabilities (CN¥128.4M).
Long Term Liabilities: 301211's short term assets (CN¥1.9B) exceed its long term liabilities (CN¥13.3M).
Debt to Equity History and Analysis
Debt Level: 301211 is debt free.
Reducing Debt: 301211 has no debt compared to 5 years ago when its debt to equity ratio was 9.2%.
Debt Coverage: 301211 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 301211 has no debt, therefore coverage of interest payments is not a concern.